DK3510042T3 - Fremgangsmåde til rensning af antistoffer - Google Patents

Fremgangsmåde til rensning af antistoffer Download PDF

Info

Publication number
DK3510042T3
DK3510042T3 DK17786994.8T DK17786994T DK3510042T3 DK 3510042 T3 DK3510042 T3 DK 3510042T3 DK 17786994 T DK17786994 T DK 17786994T DK 3510042 T3 DK3510042 T3 DK 3510042T3
Authority
DK
Denmark
Prior art keywords
antibodies
purification
Prior art date
Application number
DK17786994.8T
Other languages
English (en)
Inventor
Andre C Dumetz
Kent E Goklen
Nicholas E Levy
Jessica Rachel Molek
Andrew S Thomson
Kenneth G Yancey
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Application granted granted Critical
Publication of DK3510042T3 publication Critical patent/DK3510042T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
DK17786994.8T 2016-09-07 2017-09-06 Fremgangsmåde til rensning af antistoffer DK3510042T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384240P 2016-09-07 2016-09-07
PCT/IB2017/055374 WO2018047080A1 (en) 2016-09-07 2017-09-06 Methods for purifying antibodies

Publications (1)

Publication Number Publication Date
DK3510042T3 true DK3510042T3 (da) 2024-06-10

Family

ID=60138654

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17786994.8T DK3510042T3 (da) 2016-09-07 2017-09-06 Fremgangsmåde til rensning af antistoffer

Country Status (14)

Country Link
US (2) US11530238B2 (da)
EP (2) EP4389757A3 (da)
JP (3) JP7058272B2 (da)
KR (1) KR102489451B1 (da)
CN (1) CN109689675A (da)
AU (1) AU2017323583A1 (da)
BR (1) BR112019004459A2 (da)
CA (1) CA3035853A1 (da)
DK (1) DK3510042T3 (da)
ES (1) ES2979153T3 (da)
IL (1) IL265016B (da)
RU (1) RU2759909C2 (da)
SG (1) SG11201901059QA (da)
WO (1) WO2018047080A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2759909C2 (ru) * 2016-09-07 2021-11-18 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы очистки антител
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TW202000891A (zh) * 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
CA3117430A1 (en) * 2018-05-04 2019-11-07 Sigma-Aldrich Co. Llc Engineered cells with modified host cell protein profiles
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
JP2023500775A (ja) * 2019-09-23 2023-01-11 メルク・シャープ・アンド・ドーム・エルエルシー 宿主細胞タンパク質が減少し、ポリソルベート-80安定性が増加した、抗ctla4モノクローナル抗体を含む方法および組成物
WO2021222120A1 (en) * 2020-04-27 2021-11-04 Alexion Pharmaceuticals, Inc. Protein a chromatography purification of an antibody
CN113281430A (zh) * 2021-05-11 2021-08-20 苏州君盟生物医药科技有限公司 一种双特异性抗体的分离鉴定方法
CN115161308A (zh) * 2022-06-13 2022-10-11 江苏丰华生物制药有限公司 一种注射用替奈普酶上清液的纯化方法
EP4677364A1 (en) * 2023-03-03 2026-01-14 UCB Biopharma SRL Method for host cell protein detection
EP4438614A1 (en) * 2023-03-31 2024-10-02 Sanofi Methods for purifying heteromultimeric antibodies
WO2025133047A1 (en) 2023-12-22 2025-06-26 Novo Nordisk A/S System and methods for counter-current filtration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1584242B1 (en) 2001-06-01 2010-01-20 Upfront Chromatography A/S Fractionation of protein containing mixtures
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
CN100403028C (zh) 2002-05-31 2008-07-16 印度农业研究委员会 Bt-cry毒素的迅速检测
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
EP1786827A4 (en) 2004-05-14 2008-10-29 Kirin Holdings Kk PROCESS FOR IMMUNOGLOBULINE CLEANING
CN101365948B (zh) 2006-01-06 2012-11-07 Emd密理博公司 亲和层析基质及其制备和使用方法
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
EP2738179A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
AR062711A1 (es) * 2006-09-08 2008-11-26 Wyeth Corp Lavado de arginina en l a purificacion de proteinas usando cromatografia de afinidad
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
ES2978373T3 (es) * 2008-08-14 2024-09-11 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
JP6147726B2 (ja) 2011-03-29 2017-06-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC タンパク質精製のためのバッファー系
TWI625335B (zh) * 2013-03-15 2018-06-01 Glaxosmithkline Intellectual Property (No. 2) Limited 純化抗體的方法
JP2016519145A (ja) 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3683232A1 (en) * 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
RU2759909C2 (ru) * 2016-09-07 2021-11-18 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы очистки антител

Also Published As

Publication number Publication date
US20230046182A1 (en) 2023-02-16
WO2018047080A1 (en) 2018-03-15
KR20190043601A (ko) 2019-04-26
KR102489451B1 (ko) 2023-01-16
ES2979153T3 (es) 2024-09-24
JP2024037787A (ja) 2024-03-19
RU2019109975A3 (da) 2020-12-17
BR112019004459A2 (pt) 2019-05-28
CN109689675A (zh) 2019-04-26
EP4389757A2 (en) 2024-06-26
EP3510042A1 (en) 2019-07-17
IL265016B (en) 2021-10-31
US11530238B2 (en) 2022-12-20
RU2759909C2 (ru) 2021-11-18
JP2019530744A (ja) 2019-10-24
CA3035853A1 (en) 2018-03-15
RU2019109975A (ru) 2020-10-08
JP2022058441A (ja) 2022-04-12
SG11201901059QA (en) 2019-03-28
EP3510042B1 (en) 2024-05-22
JP7058272B2 (ja) 2022-04-21
AU2017323583A1 (en) 2019-03-14
EP4389757A3 (en) 2025-01-01
US20210284686A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
DK3268390T3 (da) Fremgangsmåder til oprensning af bispecifikke antistoffer
IL263690A (en) Purification of multispecific antibodies
DK3563156T3 (da) Fremgangsmåde til separering af biomolekyler
DK3134506T4 (da) Fremgangsmåder til oprensning af messenger rna
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK4008782T3 (da) Fremgangsmåder til tilvejebringelse af enkeltstrenget rna
DK3113858T3 (da) Fremgangsmåde til oprensning af il-15/il-15ralpha-baserede konjugater
HUE048782T2 (hu) Immunoglobulin tisztítása elõtisztítási lépések alkalmazásával
DK3301115T3 (da) Kontinuerlig flertrinsfremgangsmåde til oprensning af antistoffer
DK3473621T3 (da) Fremgangsmåde til fremstilling af diphenylmethan-derivat
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3287523T3 (da) Fremgangsmåde til sekretorisk fremstilling af protein
DK3458100T3 (da) Selektiv reduktion af cystein-manipulerede antistoffer
DK3515990T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3122444T3 (da) Fremgangsmåde til fremstilling af membraner
DK3665173T3 (da) Ny fremgangsmåde til yntetisering af amanitiner
IL265016B (en) Methods for purifying antibodies
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3334747T5 (da) Ladet dybdefiltrering af antigenbindende proteiner
DK3558347T3 (da) Fremgangsmåde til behandling af allergi med allergenspecifikke monoklonale antistoffer
DK3218396T3 (da) Fremgangsmåde til fremstilling af højaffinitets antistoffer
DK3661562T3 (da) Fremgangsmåde til konjugation af cys-mabs
DK3347481T3 (da) Fremgangsmåde til oprensning af biomassehydrolysat
DK3147369T3 (da) Fremgangsmåde til produktion af fibroinlignende protein